Sven de Vos
Division of Hematology/Oncology
David Geffen School of Medicine at University of California
Los Angeles
Los Angeles
USA
Name/email consistency: high
- Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma. de Vos, S., Goy, A., Dakhil, S.R., Saleh, M.N., McLaughlin, P., Belt, R., Flowers, C.R., Knapp, M., Hart, L., Patel-Donnelly, D., Glenn, M., Gregory, S.A., Holladay, C., Zhang, T., Boral, A.L. J. Clin. Oncol. (2009)
- Gene expression profile of serial samples of transformed B-cell lymphomas. de Vos, S., Hofmann, W.K., Grogan, T.M., Krug, U., Schrage, M., Miller, T.P., Braun, J.G., Wachsman, W., Koeffler, H.P., Said, J.W. Lab. Invest. (2003)